CliffBio
small molecule

ZYCUBO

COPPER HISTIDINATE

Loss of exclusivityJanuary 2033FDA regulatory exclusivity expiry
CompanySentynl Therapeutics, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameZYCUBO
Active ingredientCOPPER HISTIDINATE
Strength2.9MG/VIAL
Dosage formPOWDER
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJanuary 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-520January 2033
NCEJanuary 2031

More from Sentynl Therapeutics, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.